

#### From the INTERNATIONAL BUREAU

### **PCT**

### **\*NOTIFICATION OF ELECTION**

(PCT Rule 61.2)

To:

Commissioner
US Department of Commerce
United States Patent and Trademark
Office, PCT
2011 South Clark Place Room
CP2/5C24
Arlington, VA 22202

Date of mailing (day/month/year)

29 August 2001 (29.08.01)

ETATS-UNIS D'AMERIQUE
in its capacity as elected Office

International application No.
PCT/US00/17685

International filing date (day/month/year)
28 June 2000 (28.06.00)

Applicant

CHAND, Pooran et al

1.	The designated Office is hereby notified of its election made:
	X in the demand filed with the International Preliminary Examining Authority on:
	24 January 2001 (24.01.01)
	in a notice effecting later election filed with the International Bureau on:
2.	The election X was
	was not
	made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).

The International Bureau of WIPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

Authorized officer

Maria KIRCHNER

Telephone No.: (41-22) 338.83.38

Facsimile No.: (41-22) 740.14.35



## **PCT**

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference 1663/00166	FOR FURTHER ACTIO	N See Notifi Prelimin	(416)		
International application No.	International filing date (d	ay/month/year)	Priority date (day/month/year)		
PCT/US00/17685	28 JUNE 2000		28 JUNE 1999		
International Patent Classification (IPC) Please See Supplemental Sheet.	or national classification an	d IPC			
Applicant BIOCRYST PHARMACEUTICALS, I	NC.				
<ol> <li>This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.</li> </ol>					
2. This REPORT consists of a	total ofsheets.				
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority. (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).					
These annexes consist of a to	tal of sheets.				
3. This report contains indication	ns relating to the followin	g items:			
I X Basis of the repo	ort				
II Priority		•			
III Non-establishme	ent of report with regard to	o novelty, inven	tive step or industrial applicability		
IV X Lack of unity of	invention				
Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability, citations and explanations supporting such statement					
VI Certain documents	cited				
VII Certain defects in	the international application	ı			
VIII Certain observation					
•					
Date of submission of the demand	1	Date of completion	on of this report		
24 JANUARY 2001		09 OCTOBER 2001			
Name and mailing address of the IPEA		uthorized office	Budges for		
Commissioner of Patents and Trademarks Box PCT		TAOFIQ A. SOLOLA			
Washington, D.C. 20231		relephone No.	(703) 308-1235		
Facsimile No. (703) 305-3230		crephone ivo.	(103) 308-1233		

# INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/17685

1. With regard to the elements of the	
1. With regard to the elements of the international application:*	
the international application as originally filed	
x the description:	
pages 1-39 pages NONE	
pages NONE	, as originally filed
pages NONE , filed w	ith the letter of
X the claims:	
pages 40-49	
pagesNONE	, as originally file
pages NONE	ided (together with any statement) under Article 10
pagesNONE filed with the letter	, filed with the demand
——————————————————————————————————————	of, filed with the demand
X the drawings:	
pagesNONE	
pagesNONE	, as originally filed
pages NONE , filed with	, as originally filed the letter of
[V] 4	the letter of
X the sequence listing part of the description:	
pages NONE	, as originally filed
pages NONE , filed with	, as originally filed
pages NONE , filed with	the letter of
the language of a translation furnished for the purposes of the language of publication of the international application	Under Dula 40 24 v
uie language of the translation furnished for the	Trational prolimina
or 55.3).	and other preliminary examination (under Rules 55.2 and
. With regard to any nucleotide and/or amino acid sequence discle preliminary examination was carried out on the basis of the sequence.	
preliminary examination was carried out on the basis of the sequ	osed in the international application, the international
1 1	ence listing:
contained in the international application in printed form.	one name.
I liled together with the international	nsting.
the international application in computer	nsting.
filed together with the international application in computer furnished subsequently to this Authority in written form	nsting.
I diffished subsequently to this Authority in written form.	r readable form.
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readals	r readable form.
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readab  The statement that the subsequently furnished written sequence international application as filed has been furnished	r readable form.  ele form.  elisting does not go beyond the disclosure in the
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readab  The statement that the subsequently furnished written sequence international application as filed has been furnished	r readable form.  ele form.  elisting does not go beyond the disclosure in the
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readab  The statement that the subsequently furnished written sequence international application as filed has been furnished	r readable form.  ele form.  elisting does not go beyond the disclosure in the
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.	r readable form.  ele form.  elisting does not go beyond the disclosure in the
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable.  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation, of:	r readable form.  ele form.  elisting does not go beyond the disclosure in the
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable.  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation, of:  X the description, pages NONE	r readable form.  ele form.  elisting does not go beyond the disclosure in the
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readal.  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation, of:  X the description, pages NONE  The claims, Nos. NONE	r readable form.  ele form.  elisting does not go beyond the disclosure in the
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readal.  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation, of:  X the description, pages NONE  X the claims, Nos. NONE  X the drawings, sheets/fig NONE	r readable form.  ele form.  elisting does not go beyond the disclosure in the form is identical to the writen sequence listing has
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation, of:  X the description, pages NONE  X the claims, Nos. NONE  X the drawings, sheets/fig NONE  This report has been drawn as if (some of) the several services.	r readable form.  ele form.  elisting does not go beyond the disclosure in the form is identical to the writen sequence listing has
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable.  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation of:  X the description, pages NONE  X the claims, Nos. NONE  X the drawings, sheets/fig NONE  This report has been drawn as if (some of) the amendments had not beyond the disclosure as filed as in the claim.	r readable form.  Ilsting does not go beyond the disclosure in the form is identical to the writen sequence listing has been made, since they have been considered to as
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readal.  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation of:  X the description, pages NONE  X the claims, Nos. NONE  X the drawings, sheets/fig NONE  This report has been drawn as if (some of) the amendments had not beyond the disclosure as filed, as indicated in the Supplemental Bother which the statement sheat which the	r readable form.  Ple form.  Ilsting does not go beyond the disclosure in the form is identical to the writen sequence listing has been made, since they have been considered to go (Rule 70.20)**
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation, of:  X the description, pages NONE  X the claims, Nos. NONE  X the drawings, sheets/fig NONE  This report has been drawn as if (some of) the amendments had not beyond the disclosure as filed, as indicated in the Supplemental Both this report as "originally filed" and are not annexed to this report stand 70.17).	been made, since they have been considered to go  (Rule 70.2(c)).**
furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readal.  The statement that the subsequently furnished written sequence international application as filed has been furnished.  The statement that the information recorded in computer readable been furnished.  X The amendments have resulted in the cancellation, of:  X the description, pages NONE  X the claims, Nos. NONE  X the drawings, sheets/fig NONE  This report has been drawn as if (some of) the amendments had not beyond the disclosure as filed as in the statement of the sheet of the subsequently in written form.	been made, since they have been considered to go  (Rule 70.2(c)).**

### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/US00/17685

IV.	Lack of unity of invention
1.	In response to the invitation to restrict or pay additional fees the applicant has:
	restricted the claims.
	X paid additional fees.
	paid additional fees under protest.
	neither restricted nor paid additional fees.
2.	This Authority found that the requirement of unity of invention is not complied with and chose, according to Rule 68 not to invite the applicant to restrict or pay additional fees.
3.	This Authority considers that the requirement of unity of invention in accordance with Rules 13.1, 13.2 and 13.3 is
	complied with.
	x not complied with for the following reasons:
	This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.  Group 1, claim(s)1 and 6, drawn to isoxazoline derivatives and their process of making.  Group II, claim(s) 2, drawn to a process of making cyclopentene.  Group IV, claim(s) 3, drawn to a second process of making isoxazoline derivatives.  Group IV, claim(s) 4, drawn to a second process of making cyclopentene.  The inventions listed as groups I-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the technical feature common to all the groups is cyclopentene. However, cyclopentene is well known in the art and therefore cannot constitute a special technical feature under PCT Rules 13.1 and 13.2.
	<ul> <li>4. Consequently, the following parts of the international application were the subject of international preliminary examination in establishing this report:  <ul> <li>X all parts.</li> <li>the parts relating to claims Nos.</li> <li>.</li> </ul> </li> </ul>





International application No.

PCT/US00/17685

ontinuat	tion of: Boxes I	· VIII				Sheet 10
	FICATION: The International 1 C07C 61/06, 62/1	Patent Classification ( 8, 205/55, 229/28;	(IPC) and/or the Nati C07D 261/20 and US	onal classification are Cl.: 548/241; 560	e as listed below: /125, 126; 562/504	
•						

### (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

## (19) World Intellectual Property Organization International Bureau



### 

### (43) International Publication Date 4 January 2001 (04.01.2001)

#### PCT

## (10) International Publication Number WO 01/00558 A1

(51) International Patent Classification<sup>7</sup>: 62/18, 205/55, 229/28, C07D 261/20

C07C 61/06,

(21) International Application Number: PCT/US00/17685

(22) International Filing Date: 28 June 2000 (28.06.2000)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 60/140,840

28 June 1999 (28.06.1999) US

(71) Applicant (for all designated States except US): BIOCRYST PHARMACEUTICALS, INC. [US/US]; 2190 Parkway Lake Drive, Birmingham, AL 35244 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): CHAND, Pooran [IN/US]; 509 Creekwood Place, Birmingham, AL 35226 (US). ELLIOTT, Arthur, J. [US/US]; 7 Roan Court, P.O. Box 1302, Sonoita, AZ 85637 (US).

(74) Agents: AMERNICK, Burton, A. et al.; Pollock, Vande Sande & Amernick, Suite 800, 1990 M Street, N.W., Washington, DC 20036 (US). (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

#### Published:

- With international search report.
- Before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments.

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

/00558 A

(54) Title: PREPARATION OF SUBSTITUTED CYCLOPENTANE AND CYCLOPENTENE COMPOUNDS AND CERTAIN INTERMEDIATES

(57) Abstract: The invention relates to methods for preparing substituted cyclopentene compounds, their intermediates and use as neuraminidase inhibitors.

### INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/17685

	SSIFICATION OF SUBJECT MATTER		ļ	
IPC(7) :C07C 61/06, 62/18, 205/55, 229/28; C07D 261/20				
US CL :	US CL:548/241; 560/125, 126; 562/504 According to International Patent Classification (IPC) or to both national classification and IPC			
	ocumentation searched (classification system followed	by classification symbols)		
		<b>5,</b> 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5, 5,		
U.S. : :	548/241; 560/125, 126; 562/504			
Documentat	Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched			
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)  CAS ONLINE				
C. DOC	UMENTS CONSIDERED TO BE RELEVANT			
Category*	Citation of document, with indication, where app	propriate, of the relevant passages	Relevant to claim No.	
X  A	PARK, et al. Diastereoselective Synthesis of Cyclopentanoids with Hydantoin and Isoxazoline Substituents. J. Org. Chem. 1998, Vol. 63, No. 1, pages 113-117. See page 113, col. 1, lines 12-15, col. 2, lines 21-25. See also scheme 1, page 114.  WO 99/33781 (BIOCRYST PHARMACEUTICALS, INC.) 08 July 1999 (08.07.99), examples 39-45, pages 68-73.		1  2-6	
X,P  A,P			6  1-5	
Purt	her documents are listed in the continuation of Box C	. See patent family annex.		
-A* de	pecial estegories of cited documents:  comment defining the general state of the art which is not considered be of particular relevance	To later document published after the ir date and not in conflict with the ap the principle or theory underlying t	plication but eited to understand he invention	
.E. e	ritier document published on or after the international filing date	"X" document of particular relevance; considered novel or cannot be consi when the document is taken alone	the claimed invention cannot be dered to involve an inventive step	
cited to establish the publication date of another citation or other  special reason (as specified)  document of particular relevance; the claimed investive at involve an inventive step when the combined with one or more other such documents, to an oral disclosure, use, exhibition or other		ve step when the document is uch documents, such combination		
"P" d	esus  ocument published prior to the international filing date but later than	being obvious to a person skilled in "&" document member of the same pate		
	e priority date claimed c actual completion of the international search	Date of mailing of the international s	search report	
06 OCT	OBER 2000	120	B 1118 CO15	
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231  Authorized officer TAOFIQ A. SOVOLA			Drivigio	
Facsimile		Telephone No. (703) 308-1235	<u> </u>	

### INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/17685

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
Claims Nos.:     because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
2 Chima Nasa
Claims Nos.:  because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
Please See Extra Sheet.
As all required additional search fees were timely paid by the applicant, this international search report covers all searchab claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payme of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this international search report cover only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this international search report restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest
No protest accompanied the payment of additional search fees.

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/US00/17685

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION WAS LACKING This ISA found multiple inventions as follows:

This application contains the following inventions or groups of inventions which are not so linked as to form a single inventive concept under PCT Rule 13.1. In order for all inventions to be searched, the appropriate additional search fees must be paid.

Group I, claim(s)1 and 6, drawn to isoxazoline derivatives and a process of making the derivatives.

Group II, claim(s) 2, drawn to a process of making cyclopentene.

Group III, claim(s) 3, drawn to a second process of making cyclopentene.

Group IV, claim(s)4, drawn to a second process of making isoxazoline derivatives.

Group V, claim(s) 5, drawn to a third process of making cyclopentene.

The inventions listed as Groups 1-V do not relate to a single inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: the technical feature common to the groups is cyclopentene. However, cyclopentene is well known in the art and therefore cannot constitute a special technical feature under PCT Rules 13.1 and 13.2.